Advanced Non-small Cell Lung Cancer Research Articles

Algorithme thérapeutique des CBNPC sans mutation addictive

The development of immunotherapy in first-line therapy with anti-PD-1 and anti-PD-L1 has changed the first line treatment algorithm of advanced NSCLC. The anti-PD-(L)1 pembrolizumab, atezolizumab and cemiplimab clearly improve the overall survival in NSCLC with high PD-L1 expression (≥ 50 % of tumour cells), comparatively to cytotoxic chemotherapy. Combinations of anti-PD(L)-1 to platinum-based chemotherapy are superior to chemotherapy alone, regardless of PD-L1 level of expression. They represent the 1st line gold-standard when PD-L1 is expressed in less than 50 % of tumour cells and might reduce the risk of early disease progression in comparison with pembrolizumab when PD-L1 ≥ 50 %. The room for anti-CTLA-4 + anti-PD(L)-1 combinations which are not available in France remains to be established. Second-line treatment is currently based on chemotherapy, with a platinum-based doublet for patients treated in first line by pembrolizumab alone, and standard second-line chemotherapy options for patients treated by chemotherapy-immunotherapy combinations, i.e. docetaxel regardless of histology or pemetrexed for non-squamous cell carcinoma when not used in first line. Addition of an antiangiogenic agent to docetaxel only achieved a modest improvement of overall survival but neither nintedanib, nor docetaxel is available in France. Combination of paclitaxel and bevacizumab is also an option. Immunotherapy still benefits only a minority of patients whose identification is imperfect, underscoring the need for new strategies based on ne< combination amplifying the anti-tumour immune response as well as understanding the mechanisms of resistance to treatment in order to improve these results.1877-1203/© 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved.

MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC

MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC

P3.06E.04 Genetic and Immunological Backgrounds in Advanced NSCLC Patients Treated with Immunotherapy - NGS and Flow Cytometry Analysis

P3.06E.04 Genetic and Immunological Backgrounds in Advanced NSCLC Patients Treated with Immunotherapy - NGS and Flow Cytometry Analysis

P1.12A.12 Liquid Biopsy Based Risk Stratification and Intensification of Treatment in EGFR Mutant Advanced NSCLC (L-BRITE) Preliminary Analysis

P1.12A.12 Liquid Biopsy Based Risk Stratification and Intensification of Treatment in EGFR Mutant Advanced NSCLC (L-BRITE) Preliminary Analysis

OA09.06 Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12

OA09.06 Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12

First-line treatment for advanced NSCLC in older patients and those with poor performance status.

First-line treatment for advanced NSCLC in older patients and those with poor performance status.

Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18

IntroductionThe role of maintenance durvalumab after definitive concurrent chemoradiotherapy (CCRT) in unresectable locally advanced NSCLC with EGFR mutation or ALK translocation remains unclear. We compared the effectiveness of durvalumab maintenance therapy in groups with EGFR/ALK wild-type versus those with EGFR or ALK mutations. MethodsIn this retrospective multicenter observational study, patients with locally advanced NSCLC without progression after CCRT followed by maintenance durvalumab and available molecular test results (EGFR and ALK) were eligible. The primary objective was to compare progression-free survival (PFS) between EGFR/ALK wild-type and EGFR or ALK mutant NSCLC. Secondary objectives include overall survival according to EGFR or ALK mutation and programmed death-ligand 1 (PD-L1) expression. ResultsAmong 339 patients, 279 had wild-type EGFR/ALK, 41 had EGFR mutations and 19 had ALK translocations. The median age was 68 years with 276 male individuals (81.4%) and 63 female individuals (18.6%), 165 (49.3%) had adenocarcinoma, 149 (44.5%) had squamous cell carcinoma, and 21 (6.3%) had other histologic types, 120 (35.4%) had stage IIIA, 168 (49.6%) stage IIIB, and 51 (15.0%) had stage IIIC. Most of the patients (n = 288, 85%) achieved partial response to CCRT, two (0.6%) had a complete response, and 49 patients (14.4%) had stable disease. Excluding four patients with unknown PD-L1 tumor proportion score (TPS), 16 (4.8%) had a PD-L1 TPS of 0, 168 (50.1%) had 1 to 49, and 151 (45.1%) had 50 or higher. The median PFS was 21.4 months (95% confidence interval [CI]: 17.3–25.3) for the EGFR/ALK wild-type group and 21.0 months (95% CI: 15.7–not available [NA]) for the EGFR or ALK mutant group with no significant difference (p = 0.74). Significant differences occurred in PFS on the basis of PD-L1 expression with values of 13.6 (95% CI: 10.5–NA), 18.7 (95% CI: 15.1–26.9), and 24.7 (95% CI: 20.7–NA) months for TPS of 0, 1–49, and 50 or higher, respectively (p = 0.02). ConclusionsDurvalumab maintenance therapy after definitive CCRT in unresectable locally advanced NSCLC patients with EGFR or ALK mutation demonstrates comparable clinical outcomes to those with wild-type EGFR/ALK when PD-L1 expression is present.

MO35-3 A phase II study of weekly carboplatin and concurrent radiotherapy for locally advanced NSCLC in elderly patients

MO35-3 A phase II study of weekly carboplatin and concurrent radiotherapy for locally advanced NSCLC in elderly patients

P3.12E.05 Real-World Comparative Effectiveness of Sotorasib vs Docetaxel as 2L/2L+ Treatment of KRAS G12c-Mutated Advanced NSCLC

P3.12E.05 Real-World Comparative Effectiveness of Sotorasib vs Docetaxel as 2L/2L+ Treatment of KRAS G12c-Mutated Advanced NSCLC

P2.10A.06 Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC with EGFR/Other Genomic Alterations

P2.10A.06 Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC with EGFR/Other Genomic Alterations

P4.15E.03 Assessing the Utilization of Palliative Care in Advanced NSCLC Patients with Brain Metastases

P4.15E.03 Assessing the Utilization of Palliative Care in Advanced NSCLC Patients with Brain Metastases

EP.12A.03 Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US

EP.12A.03 Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US

EP.11A.23 REAL-IMPACT: Real-World Effectiveness of Immunotherapy in PD-L1 Negative Advanced NSCLC - A Multicenter Cohort Study in Argentina

EP.11A.23 REAL-IMPACT: Real-World Effectiveness of Immunotherapy in PD-L1 Negative Advanced NSCLC - A Multicenter Cohort Study in Argentina

P1.06B.11 Plasma MicroRNAs Profiling to Monitor Immunotherapy Response in Advanced NSCLC Patients

P1.06B.11 Plasma MicroRNAs Profiling to Monitor Immunotherapy Response in Advanced NSCLC Patients

EP.12D.02 Treatment Strategies and Survival Outcomes of Advanced NSCLC with HER2 Mutation and BM: A Multicenter Retrospective Study

EP.12D.02 Treatment Strategies and Survival Outcomes of Advanced NSCLC with HER2 Mutation and BM: A Multicenter Retrospective Study

P2.10B.04 Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study

P2.10B.04 Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study

P3.12C.05 Thromboembolic Events in Patients with Oncogene-Addicted Advanced NSCLC

P3.12C.05 Thromboembolic Events in Patients with Oncogene-Addicted Advanced NSCLC

EP.12E.01 OBX02-011, a Novel Oral ALK and EGFR Dual-target Tyrosine Kinase Inhibitor for the Treatment of Advanced NSCLC Patients

EP.12E.01 OBX02-011, a Novel Oral ALK and EGFR Dual-target Tyrosine Kinase Inhibitor for the Treatment of Advanced NSCLC Patients

P4.11E.22 Treatment-Free Survival in Advanced NSCLC Patients who Terminated Immune-Checkpoint Inhibitors.

P4.11E.22 Treatment-Free Survival in Advanced NSCLC Patients who Terminated Immune-Checkpoint Inhibitors.

MA01.07 Long-Term Analysis of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy (ccrt) -/+ Metformin in Locally Advanced NSCLC.

MA01.07 Long-Term Analysis of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy (ccrt) -/+ Metformin in Locally Advanced NSCLC.